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Abstract
Purpose—To contrast rates of initial HPV vaccine uptake, offered at no cost, between a rural 
clinic, a rural community college, and an urban college clinic and to identify rural versus urban 
differences in uptake of free booster doses.
Methods—Young rural women attending rural clinics (n = 246), young women attending a rural 
community college (n = 251) and young women attending an urban university health clinic (n = 
209) were recruited in Kentucky. After completing a brief questionnaire, women received a free 
voucher for HPV vaccination. Whether women redeemed the voucher for the initial dose of 
vaccine served as the study outcome variable.
Findings—In controlled analyses, the contrast in initial uptake between urban clinic women 
(reference category) and rural college women was significant (P < .0001). However, the contrast 
in initial uptake between urban clinic women (reference category) and rural clinic women was not 
significant (P = .42). The model predicting uptake of subsequent doses among those with initial 
uptake (n = 235) also indicated significant differences as a function of recruitment location, with 
rural clinic women being about 7 times more likely than urban clinic women (P < .0001) to not 
return for at least 1 follow-up dose. The contrast between urban clinic women and rural college 
women was also significant (P = .014).
Conclusion—Initial uptake of free HPV vaccination among young rural college women may be 
problematic. Moreover, uptake of subsequent free doses among rural women may be problematic 
regardless of whether contact is made in a clinic or through college recruitment.
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Human Papillomavirus (HPV) vaccination is approved and recommended for use in females 
from 9 to 26 years of age.1 The vaccine protects against HPV types 16 and 18, which are 
For further information, contact: Richard A. Crosby, PhD, College of Public Health at the University of Kentucky, 121 Washington 
Avenue, Suite 113, Lexington, KY 40506; crosby@uky.edu. 
HHS Public Access
Author manuscript
J Rural Health. Author manuscript; available in PMC 2016 February 15.
Published in final edited form as:













implicated in about two-thirds of cervical cancers.1 The Advisory Committee on 
Immunization Practices (ACIP) recommends “catch-up vaccination” for females 13–26 
years of age.1 Unfortunately, little research has been focused upon women in the higher end 
of this “catch-up” age range (ie, 18–26 years of age). Indeed, the extant research on 
behavioral acceptance of the vaccine is primarily centered on younger girls, with studies of 
older girls being restricted to intent rather than actual uptake.2–7 Thus, one potentially timely 
and important research question involves the actual uptake of the vaccine by older girls/
young women.
From a behavioral perspective, the challenges associated with initial uptake (dose 1) of the 
HPV vaccine may be quite different from those associated with receipt of subsequent doses 
(dose 2 at 2 months and dose 3 at 6 months). One general factor that may be an important 
determinant of uptake is rural versus urban residence. In fact, related evidence suggests that 
rural health disparities may function with respect to cervical cancer prevention.8–10 
Accordingly, the purpose of this study was to contrast rates of HPV vaccine uptake between 
young women recruited from 2 rural locations and 1 urban location. We hypothesized that 
uptake would be significantly lower among women recruited in the rural locations, even 
after controlling for rural upbringing and other potentially confounding variables.
Methods
Study Sample
Using the Beale codes from the Economic Research Service,11 our urban location was 
ranked as “2” meaning that it is a county in a metro area of 250,000 to 1 million people. By 
contrast, our selected rural counties had Beale codes ranging from “7” through the most 
rural designation of “9.” A code of 7 designates the county as having a population of less 
than 20,000 people and being non-adjacent to a metropolitan area.
Urban Recruitment—From October 2007 through May of 2008 research assistants 
recruited women attending the University Health Service at the University of Kentucky. 
Recruitment occurred in the waiting area reserved for women seeking routine gynecological 
care. Women were eligible to participate if they were 18 to 24 years old and had not been 
vaccinated with Gardasil (the only HPV vaccine approved for use at the time). Because 
doses 2 and 3 were, for some women, due during summer months, eligibility was also 
restricted to women indicating they lived within a 50-mile radius of the university. Of 231 
eligible women, 209 (90.9%) agreed to participate in the study and provided written 
informed consent.
Rural Recruitment—Two locations were used: a rural clinic and a rural community 
college. Both locations were in southeastern Kentucky—an area of rural Appalachia 
characterized by a predominately white population, poverty, and medially underserved 
residents.12 The selected area of Kentucky has also experienced a high rate of cervical 
cancer incidence. From 2003–2007, the age-adjusted incidence rate for cervical cancer in 
Kentucky was 9.22 per 100,000; the US age-adjusted rate for the same time period was 8.1. 
The age-adjusted incidence rate for cervical cancer in Appalachia Kentucky was 10.78 and 
the age-adjusted incidence rate for cervical cancer in the selected study area was 9.25.13
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From March 2008 through September 2009, a research assistant recruited female patients in 
any of 5 regional health clinics located in 5 rural counties of southeastern Kentucky. During 
that same time period, a second research assistant recruited women attending a local 
community college (with buildings located in 4 of the same 5 counties used for the clinic 
sample). Women were eligible if they were not pregnant, 18–26 years old, and had not been 
vaccinated with Gardasil. Of 505 eligible women, 495 (98%) agreed to participate in the 
study and provided written informed consent. Of these, 246 were recruited from clinics and 
251 were recruited from the community college. The Institutional Review Board at the 
University of Kentucky approved the study protocols.
Procedures
Recent findings suggest that insurance coverage14–16 and cost17 may be strongly associated 
with initial uptake. Thus, to control for these “cost” factors we determined that a study 
providing the vaccine for free was needed. In essence, because Gardasil was not universally 
covered by insurance plans, the cost barrier was removed to more effectively test the study 
hypothesis. However, the fact that Gardasil would be provided at no cost was not advertised 
or disclosed until after the questionnaire was completed and young women were 
compensated for their time. To avoid self-selection bias, the project was called the Women’s 
Health Study. Women completed a brief questionnaire and they were compensated for their 
time. After being compensated, the research assistant provided women with a voucher to 
receive free Gardasil at the clinic they were recruited from or, in the case of college women, 
a centrally located clinic. These coupons were coded with ID numbers that matched the ID 
numbers recorded on the women’s questionnaires. Redeemed coupons were used to create a 
freestanding set of medical records indicating Gardasil uptake.
Data Analysis
The descriptive analysis comparing uptake across the 3 recruitment sites was based on 3 × 2 
chi-square tests, with 2 × 2 chi-square tests being conducted on a post hoc basis following a 
significant P value on a 3 × 2 test. To test the study hypothesis, we included a measure of 
rural upbringing (not always the same as rural residence) as a control variable. Young 
women were asked the following question. “When you were a high school student, about 
how large was your hometown?” Five response options were provided ranging from (1) a 
“large city (like Chicago, New York) or the suburban area around it” to (5) rural area. In 
addition to age, 3 other key variables were assessed as potential covariates: ever having an 
abnormal Pap test result, belief that mother “would definitely” want the daughter to be 
vaccinated, and belief that father “would definitely” want the daughter to be vaccinated. 
These 3 covariates were selected based on findings from HPV vaccine uptake studies 
previously published.14,17–19
Hierarchal logistic regression was used to control for rural upbringing and the other assessed 
covariates which differed between young women in the recruitment locations. The first 
block contained the control variables and the second block contained only the variable 
representing recruitment location. Two models were created. The first predicted initial 
uptake of the vaccine (dose 1). The second model predicted follow-up vaccination among 
those taking dose 1.
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Figure 1 displays the uptake rates for each of 3 doses and each of the 3 recruitment sites. As 
shown, dose 1 uptake was greatest among women recruited in the urban clinic (50.7%), 
followed by women recruited in the rural clinic (45.1%) and those recruited from the rural 
college (6.8%). Dose 2 uptake was also greatest among women from the urban clinic 
(39.7%), followed by women from the rural clinic (13.8%) and the rural college (2.8%). 
Dose 3 uptake was also greatest among women from the urban clinic (28.2%), with uptake 
rates from the rural clinic women (4.5%) and the rural college women (1.6%) being equally 
low (non-significant). With only 2 exceptions the differences in the uptake of each dose, 
across all 3 samples, were statistically significant (P < .001). The first exception was dose 1 
in the urban clinic compared to dose 1 in the rural clinic—the difference of 5.6% was not 
significant by chi-square test results (P = .27). The second exception was for dose 3 in the 
rural clinic (4.5%) versus the rural college (1.6%)—due to low numbers this difference was 
also not significant by chi-square test results (P = .06).
Bivariate Associations
As established in the descriptive findings shown above, recruitment location was 
significantly associated with initial uptake (dose 1) of the vaccine when contrasting the rural 
college women to the urban clinic women and when contrasting the rural clinic women to 
the rural college women. Differences between urban clinic women and rural clinic women 
were not observed (P = .27). In addition, recruitment location was significantly associated 
with return for at least one follow-up dose of the vaccine when contrasting the rural college 
women (41.2%) to the urban clinic women (78.5%) (P < .001) and when contrasting the 
rural clinic women (30.6%) to the urban clinic women (78.5%) (P < .001). Differences 
between the rural clinic women (30.6%) and the urban clinic women (78.5%) were not 
observed (P = .39).
Rural upbringing was significantly associated with uptake (P < .0001). Uptake for those not 
having a rural upbringing was 39.0%, whereas uptake was 26.6% among those who reported 
a rural upbringing. Return for subsequent doses was also significantly more likely (P = .005) 
for women without a rural upbringing (60.4% of those receiving dose 1 returned for one or 
both booster doses) compared to women reporting a rural upbringing (41.8% of those 
receiving dose 1 returned for one or both booster doses).
Age, belief that mother “would definitely” want the daughter to be vaccinated, belief that 
father “would definitely” want the daughter to be vaccinated, and ever having an abnormal 
Pap test result were each analyzed using 3 × 2 chi-square tests for their association with the 
variable representing the 3 recruitment locations. Differences for age (P < .001), mothers’ 
endorsement (P = .03), and fathers’ endorsement (P = .004) were observed. Differences 
relative to ever having an abnormal Pap test result were not observed (P = .19). Thus, the 
multivariate models were constructed to control for rural upbringing, age, mothers’ 
endorsement, and fathers’ endorsement.
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The model predicting initial uptake (n = 710) was significant (chi-square with 4df = 173.5, P 
< .0001) and achieved an excellent fit with the data (Goodness of fit chi-square with 3 df = 
3.73, P = .88). Other than mothers’ endorsement (AOR = .37; 95% CI, 0.26–0.54; P < .
0001) none of the other covariates obtained multivariate significance. Recruitment location 
was significant for the contrast between urban clinic women (reference category) and rural 
college women (AOR = 13.10; 95% CI, 7.3–23.4; P < .0001). However, the contrast 
between urban clinic women (reference category) and rural clinic women was not significant 
(AOR = 1.18; 95% CI, 0.79–1.78; P = .42).
The model predicting subsequent doses among those with initial uptake (n = 235) was 
significant (chi-square with 4 df = 60.8, P < .0001) and achieved satisfactory fit with the 
data (Goodness of fit chi-square with 7 df = 4.03, P = .78). The effect of age was significant 
(AOR = 1.21; 95% CI, 1.05–1.39; P = .009), with older women being less likely to return 
for follow-up doses. None of the other covariates obtained multivariate significance. Again, 
however, recruitment location was significant, with rural clinic women being about 7 times 
more likely than urban clinic women (AOR = 6.98; 95% CI, 3.61–13.48; P < .0001) to not 
return for at least one follow-up dose. The contrast between urban clinic women and rural 
college women was also significant (AOR = 4.20; 95% CI, 1.33–13.23; P = .014).
Discussion
In an era of intensified government enthusiasm for prevention as a solution to escalating 
health care costs, the observed rate of vaccine uptake among young rural women (a 
population recognized for cervical cancer disparities) is disheartening. It appears that 
offering the vaccine for free is not enough; it must also be convenient and this factor may be 
lacking in rural areas. The extremely large discrepancy in initial uptake between women 
recruited from the 2 clinics and those recruited from community college demonstrates this 
point about convenience. Clearly, the greater initial uptake observed among clinic-recruited 
women is potentially attributable to a convenience factor. This convenience factor, of 
course, applied only to dose 1 and it explains the lack of significance between initial uptake 
in the rural versus the urban clinic. In essence, the convenience factor negated the “rural 
factor.”
Because we controlled for the influence of rural versus urban upbringing, and other likely 
confounding variables, it is fair to speculate that the observed dramatic differences in 
subsequent vaccine uptake are attributable to the rural factor. Rural clinic-recruited women 
as well as rural college-recruited women were significantly less likely to return for 
subsequent doses, even after controlling for the assessed covariates. Although there is no 
doubt that an endless number of differences may exist between rural and urban women, 
“teasing out” these differences is not a necessary exercise to promote completion of HPV 
vaccine series. It is, in fact, the case that intensified efforts are required to continue the 
vaccine series among rural women.
One possible explanation for vaccine uptake issues in rural areas is distance to the clinic. 
Distance may indeed be a key factor in the observed drop from 40% dose 2 uptake in the 
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urban clinic to just under 14% in the rural clinic and not even 3% in the sample of rural 
college students. The drop was even more dramatic when considering dose 3. However, we 
hesitate to speculate as to why the return for dose 2 was so much higher for rural women 
recruited from the clinic versus rural women recruited from the community college. Of 
course, it is possible that women recruited from the clinic had a proclivity for health care 
and that proclivity also applied to vaccination.
Findings are limited by the use of a convenience sample and the validity of the self-reported 
data pertaining to rural upbringing. It is, however, well worth noting that our use of coded 
coupons to collect the primary outcome variable (ie, vaccine uptake) is a clear asset to the 
rigor of this study. The study findings represent the first comparison of Gardasil uptake 
between young women residing in rural areas versus their urban counterparts. Although 
more in-depth investigation is required, the results provide an early demonstration 
suggesting that rural health disparities extend to the somewhat simplistic health behavior of 
HPV vaccination. This disparity may be resolved, in part, by making the vaccine available at 
easy-to-access locations (eg, larger grocery stores and community events) in rural 
communities.
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